Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

A case series reports dysesthesia and allodynia in patients treated with semaglutide and tirzepatide, suggesting a possible dose related to sensory adverse effect.

Add Yahoo as a preferred source to see more of our stories on Google. Having an oral version of the medication, which had only been available as an injectable until now, is a “very big deal,” says ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist (GLP-1) pill is more effective for weight loss than oral ...

Eli Lilly's oral GLP-1, orforglipron outperforms blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial: Our Bureau, Mumbai Saturda ...

Wegovy pill, the first FDA‑approved oral GLP‑1 for weight loss, is now available via WeightWatchers Med+ from $149 per month ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.

The findings add to competitive pressure on Novo Nordisk’s GLP-1 portfolio and come days after the Danish drugmaker reported that its next-generation obesity drug, CagriSema, did not meet its primary ...

If you miss a dose of GLP-1, you may be able to take it right away or wait until your next scheduled dose. It depends on the medication you take and how many doses you’ve missed. Glucagon-like peptide ...

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial ...